BioCentury | Nov 11, 2016
Company News

Bellicum, Bambino Gesu Children's Hospital deal

Bellicum and the hospital partnered to jointly develop CAR T cell and T cell receptor (TCR) therapies discovered by the hospital and engineered with Bellicum’s CaspaCIDe molecular safety switch technology. Bellicum will provide up to...
BioCentury | Oct 8, 2012
Product Development

Boosting mitochondria

...on this information, Edison started a six-month Phase IIa study in 10 patients at the Bambino Gesu Children's Hospital...
...patents and hopes to gain Orphan drug exclusivity for the product. Companies and Institutions Mentioned Bambino Gesu Children's Hospital...
BioCentury | Mar 5, 2009
Cover Story

Anti-flubodies

Two separate teams have isolated human antibodies that neutralize many variants of influenza antigen hemagglutinin A and prevent viral entry and infection. Both teams are developing their antibodies as therapeutics but are going after different...
Items per page:
1 - 3 of 3
BioCentury | Nov 11, 2016
Company News

Bellicum, Bambino Gesu Children's Hospital deal

Bellicum and the hospital partnered to jointly develop CAR T cell and T cell receptor (TCR) therapies discovered by the hospital and engineered with Bellicum’s CaspaCIDe molecular safety switch technology. Bellicum will provide up to...
BioCentury | Oct 8, 2012
Product Development

Boosting mitochondria

...on this information, Edison started a six-month Phase IIa study in 10 patients at the Bambino Gesu Children's Hospital...
...patents and hopes to gain Orphan drug exclusivity for the product. Companies and Institutions Mentioned Bambino Gesu Children's Hospital...
BioCentury | Mar 5, 2009
Cover Story

Anti-flubodies

Two separate teams have isolated human antibodies that neutralize many variants of influenza antigen hemagglutinin A and prevent viral entry and infection. Both teams are developing their antibodies as therapeutics but are going after different...
Items per page:
1 - 3 of 3